{"id":1004868,"date":"2026-09-21T16:04:03","date_gmt":"2026-09-21T20:04:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/"},"modified":"2026-09-21T16:04:03","modified_gmt":"2026-09-21T20:04:03","slug":"xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/","title":{"rendered":"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p>VANCOUVER, BC and BOSTON, MA, Sept.  21, 2026  (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit, <\/strong>Virtual Fireside Chat: Wednesday, September 23, 2:00\u20132:25 pm ET<\/li>\n<\/ul>\n<p>Details about the presentation, including webcast information, can be found on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xILeCEixXqiUc2qPCexFjSU6ewoRlAEAq9tPt3gqpxk-bUid80F5MXttAxDtyhDSJwM0TCXvxmgVBcFvdcmR-d2wAHKh0Qw6MupYtck_y0s=\" rel=\"nofollow\" target=\"_blank\">Investors<\/a> section of Xenon&#8217;s website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change.<\/p>\n<p>\n        <strong><br \/>\n          <u>About\u00a0Xenon Pharmaceuticals Inc.<\/u><br \/>\n        <\/strong>\u00a0<\/p>\n<p>Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon\u2019s lead molecule, azetukalner, is a novel, potent K<sub>V<\/sub>7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K<sub>V<\/sub>7 and Na<sub>V<\/sub>1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D0Htp3Xc0mrfyhSSzhqk34V987e5mXVlhtb5hhw50MB8LMLVVAedGrZLCPFhIiz0qjdvvOaF8KCAdATRTI635ZwbNbwi_u67J6Gc30xxAPs=\" rel=\"nofollow\" target=\"_blank\">www.xenon-pharma.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lsWkp7BnJDwnCHHDmXh2ZgbqEtiDUV7TfG140RbPLP2bc6lcP77wIF9ljKmWZZpVZ9TPVWU28kw49ncPBspVIKvF2rwKNaJ7MTRVr4ZmaXI=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xi86oTa7TF7QnP03qCIvwJgjG32RaFh9hLg29D4bdJUJbi-1BZHqlDzg2_ZhYSxJGxntNb4VRr_iNGl41LkuEw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner.\u00a0<\/p>\n<p>\n        <strong><br \/>\n          <u>Contacts:<\/u><br \/>\n        <\/strong>\u00a0<\/p>\n<p>\n        <em>For Investors:<\/em><br \/>\n        <br \/>Laura Perry\/Emily Huang<br \/>Argot Partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UKFXpK7gvFns7oDd6Ln4I6VWHvSQPh40L2YSDH-xQwhjiPOKZ8mAwrE37zObKdKUSnxdFcYAfMKCzsRNbcguGNX9hfMTg5FpdBKkKZfKUPI=\" rel=\"nofollow\" target=\"_blank\">Xenon@argotpartners.com<\/a><\/p>\n<p>\n        <em>For Media:<\/em>\u202f\u00a0<br \/>Colleen Alabiso\u202f\u00a0<br \/>Senior Vice President, Corporate Affairs\u202f\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=69MHnmsPbYK4xy_jc-IJj6VD1BPptmJCInHujBYZy1JXk1urDB3XIL7-HrsngqhX04Iv8_cJlG7k1s1P_HYcCMreBjLchP4EI5lOghWaojo=\" rel=\"nofollow\" target=\"_blank\">media@xenon-pharma.com<\/a>\u202f\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2IxNmFjM2QtMzJlYy00ZmI5LWI3MDQtYjBkOWU2NjNkNjk0LTEwMjI5NTMtMjAyNi0wOS0yMS1lbg==\/tiny\/Xenon-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00\u20132:25 pm ET Details about the presentation, including webcast information, can be found on the Investors section of Xenon&#8217;s website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change. About\u00a0Xenon Pharmaceuticals Inc. \u00a0 Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1004868","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00\u20132:25 pm ET Details about the presentation, including webcast information, can be found on the Investors section of Xenon&#8217;s website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change. About\u00a0Xenon Pharmaceuticals Inc. \u00a0 Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, &hellip; Continue reading &quot;Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-21T20:04:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit\",\"datePublished\":\"2026-09-21T20:04:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/\"},\"wordCount\":271,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/\",\"name\":\"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA=\",\"datePublished\":\"2026-09-21T20:04:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/","og_locale":"en_US","og_type":"article","og_title":"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit - Market Newsdesk","og_description":"VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) &#8212; Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00\u20132:25 pm ET Details about the presentation, including webcast information, can be found on the Investors section of Xenon&#8217;s website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change. About\u00a0Xenon Pharmaceuticals Inc. \u00a0 Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, &hellip; Continue reading \"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-21T20:04:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit","datePublished":"2026-09-21T20:04:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/"},"wordCount":271,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/","name":"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA=","datePublished":"2026-09-21T20:04:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzMDc4MiM3ODU0NDY2IzIwMTEzODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xenon-to-present-at-td-cowen-novel-mechanisms-in-neuropsychiatry-epilepsy-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry &amp; Epilepsy Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1004868"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1004868\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1004868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1004868"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1004868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}